Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Gene Therapy Prior Auth | OpenPay…
    Ask Trek AI about this page
    ModifiedUnitedHealthcarePolicy N/A

    Gene Therapy Clinical Guideline

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs UnitedHealthcare coverage and prior authorization requirements for FDA-approved gene and cellular therapies used to treat specified inherited hematologic, neurologic, metabolic, and dermatologic disorders. It affects providers requesting gene therapy for eligible pediatric and adult patients.

    Policy Summary
    PayerUnitedHealthcare
    PolicyGene Therapy Clinical Guideline
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOct 1, 2026
    Last ReviewSep 9, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization establishing all applicable diagnosis, genetic, clinical-severity, prior-treatment, donor-availability, and transplant-related medical necessity criteria before infusion.
    SourceLink
    POLICY UPDATE CHANGES

    The guideline added medical necessity criteria for etuvetidigene autotemcel (Waskyra) for Wiskott-Aldrich syndrome.

    The guideline added genotype confirmation requirements for Casgevy and Lyfgenia.

    The guideline added medical necessity criteria for marnetegragene autotemcel (Kresladi) for severe leukocyte adhesion deficiency type I.

    The indication for elivaldogene autotemcel (Skysona) was updated because of new safety information regarding an increased risk of hematologic malignancy.

    Medical necessity criteria were added for etuvetidigene autotemcel (Waskyra) for Wiskott-Aldrich Syndrome.

    Genotype confirmation requirements were added for exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia).

    Medical necessity criteria were added for marnetegragene autotemcel (Kresladi) for treatment of severe leukocyte adhesion deficiency-type I.

    A supplemental FDA approval was added for exagamglogene autotemcel (Casgevy) in patients aged 2 years and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    8FDA-approved gene or cell therapies identified
    5Material clinical or coverage updates
    5.0Current guideline version
    2+Casgevy supplemental indication minimum age
    Increased malignancy riskSkysona safety concern

    Coverage Criteria

    Zynteglo initial therapy

    Zynteglo is considered medically necessary as a one-time single dose when all of the following are met.

    Zynteglo medical necessity: The patient has transfusion-dependent beta-thalassemia; transfusion dependence is at least 100 mL/kg/year or 8 units/year of packed red blood cell transfusions in each of the most recent two years; DNA analysis with HBB sequencing confirms a qualifying genotype; the patient is a candidate for allogeneic HSCT but is ineligible because no appropriate donor is available before mobilization, apheresis, and myeloablative conditioning; the recommended hemoglobin target is met; required infectious, hepatic, iron-overload, cardiac MRI, and oncology evaluations are documented; the patient has not previously received gene therapy for the requested diagnosis; and the patient is at least 4 years old, weighs at least 6 kg, and is reasonably expected to provide sufficient cells for manufacturing.At least 100 mL/kg/year or 8 units/year of PRB transfusions; Hb ≥11 g/dL for at least 30 days before mobilization and conditioning; age ≥4 years; weight ≥6 kg

    Qualifying genotypes include specified non-β0/β0 and β0/β0 examples.

    Casgevy initial therapy

    Casgevy is considered medically necessary as a one-time single dose when all of the following are met.

    Casgevy medical necessity: The patient is at least 2 years old with transfusion-dependent beta-thalassemia; transfusion dependence is at least 100 mL/kg/year or 10 units/year of red blood cell transfusions in each of the most recent two years; DNA analysis with HBB sequencing confirms a qualifying β0/β0-like or non-β0/β0-like genotype; the patient is a candidate for allogeneic HSCT but is ineligible because no appropriate donor is available before mobilization, apheresis, and conditioning; the recommended pre-apheresis hemoglobin goal is addressed; confirmative screening shows no HIV-1, HIV-2, HBV, or HCV; the patient has not previously received gene therapy for the requested diagnosis; and the patient has not previously received allogeneic or autologous HSCT.At least 100 mL/kg/year or 10 units/year of RBC transfusions; age ≥2 years; pre-apheresis Hb goal ≥11 g/dL

    Qualifying genotype examples include β0/β0, β0/IVS-I-110, and IVS-I-110/IVS-I-110 β+/β+ within the β0/β0-like category.

    Skysona initial therapy

    Elivaldogene autotemcel (Skysona) is considered medically necessary as a one-time single dose when all of the following are met.

    Skysona eligibility: The patient has early, active cerebral adrenoleukodystrophy; is without an available HLA-matched donor for allogeneic HSCT; is a male aged 4–17 years; is asymptomatic or mildly symptomatic with neurologic function score ≤1; has a Loes score of 0.5–9; has gadolinium enhancement on brain MRI; has a pathogenic or likely pathogenic ABCD1 variant; has elevated VLCFA levels; has completed evaluation and clearance for adequate hematologic function; has had abnormal liver function evaluated by hepatology with clearance; and, if there is a known prior or current malignancy, has oncology clearance stating the malignancy is not expected to affect survival.Male age 4–17 years; NFS ≤1; Loes score 0.5–9

    Hematology consultation is highly recommended before treatment because of hematologic malignancy risk.

    Kresladi initial therapy

    Marnetegragene autotemcel (Kresladi) is considered medically necessary as a one-time infusion when all of the following are met.

    Kresladi medical necessity

    • Qualifying severe LAD-I pathway

      • Pathway 1: Less than 2% of normal CD18-expressing PMNs and at least one grade 2 or higher bacterial or fungal infection.<2% CD18-expressing PMNs; ≥1 grade 2 or higher bacterial or fungal infection
      • Pathway 2: At least 2% of normal CD18-expressing PMNs, fewer than 2% of PMNs expressing CD11a or CD11b, and confirmed biallelic ITGB2 disease consistent with LAD-I.≥2% CD18-expressing PMNs; <2% expressing CD11a or CD11b

    Lenmeldy initial therapy

    Atidarsagene autotemcel (Lenmeldy) is considered medically necessary as a one-time infusion for children with specified MLD subtypes when the applicable criteria are met.

    Eligible MLD presentation

    • Presymptomatic late-infantile or early-juvenile MLD: The patient has confirmed presymptomatic disease classified as PSLI or PSEJ, confirmed through testing of siblings of a previously affected and diagnosed child, or through positive newborn screening followed by formal diagnostic confirmation testing.PSLI or PSEJ
    • Early symptomatic early-juvenile MLD: The patient has ESEJ MLD with GFMA-MLD 0–1 and IQ ≥85.GFMA-MLD 0–1; IQ ≥85

      Exceptions for impairments due to non-MLD comorbidities or patients close to the IQ cutoff will be considered.

    Zevaskyn initial therapy

    Zevaskyn is considered medically necessary when all of the following are met.

    Zevaskyn RDEB criteria: The patient is pediatric or adult with recessive dystrophic epidermolysis bullosa wounds; has confirmed positive expression of the NC1 region of type VII collagen in skin; has two confirmed RDEB C7 mutations with recessive inheritance or confirmation that the parents have no evidence of dominant disease; has no current systemic HIV, hepatitis B, or hepatitis C infection; has no current evidence or history of squamous cell carcinoma in targeted treatment areas; and the targeted areas have not previously been treated with Zevaskyn.Up to 12 gene-corrected keratinocyte sheets during a single surgical session

    A second cycle for existing wounds or treatment of new wounds from previously untreated sites requires additional prior authorization.

    Casgevy SCD initial therapy

    Casgevy is considered medically necessary as a one-time infusion when all of the following are met.

    Casgevy SCD criteria: The patient is at least 2 years old; molecular or genetic testing confirms genotype βs/βs, βs/β0, or βs/β+; documentation shows at least two severe VOC events per year during each of the previous two years; confirmative screening shows no HIV-1, HIV-2, HBV, or HCV; the treatment plan documents intent to transfuse before apheresis while maintaining HbS below 30% of total hemoglobin and total hemoglobin at or below 11 g/dL; the patient is an allogeneic HSCT candidate but lacks an appropriate donor; compliance with hydroxyurea or another prescribed treatment regimen is documented; and the patient has not previously received gene therapy for the requested diagnosis.At least 2 severe VOCs per year in each of 2 consecutive years; HbS <30%; total Hb ≤11 g/dL

    Lyfgenia initial therapy

    Lyfgenia is considered medically necessary as a one-time infusion when all of the following are met.

    Lyfgenia SCD criteria: The patient is at least 12 years old; molecular or genetic testing confirms genotype βs/βs, βs/β0, or βs/β+; documentation shows at least four qualifying VOEs during the prior 24 months; confirmative screening shows no HIV-1, HIV-2, HBV, or HCV; the treatment plan documents intent to transfuse to a hemoglobin target of 8–10 g/dL, not exceeding 12 g/dL, with HbS below 30%; the patient is an allogeneic HSCT candidate but lacks an appropriate donor; compliance with hydroxyurea or another prescribed treatment regimen is documented; and the patient has not previously received gene therapy for the requested diagnosis.At least 4 VOEs in the prior 24 months; hemoglobin 8–10 g/dL and not above 12 g/dL; HbS <30%

    Lyfgenia carries a boxed warning for hematologic malignancy.

    Initial therapy — applicable coverage criteria

    Coverage requires all applicable criteria.

    Applicable sickle cell disease gene therapy criteria: The member must have a molecularly or genetically confirmed βs/βs, βs/β0, or βs/β+ genotype; at least four qualifying VOEs in the prior 24 months; negative HIV-1, HIV-2, HBV, and HCV screening; a transfusion plan targeting hemoglobin 8–10 g/dL without exceeding 12 g/dL and HbS below 30%; HSCT candidacy without an appropriate donor; documented compliance with hydroxyurea or another prescribed regimen; and no prior gene therapy for the requested diagnosis.≥4 VOEs in 24 months; Hb 8–10 g/dL; HbS <30%

    Zynteglo is excluded when the patient has previously received gene therapy for the requested diagnosis.

    Casgevy is excluded when the patient has previously received gene therapy for the requested diagnosis or has undergone any prior allogeneic or autologous HSCT.

    Lenmeldy is considered unproven for children with late juvenile metachromatic leukodystrophy, patients with adult MLD, and children or adults who received treatment within the last 6 months and have residual cells of donor origin.

    Allogeneic HSCT can help arrest neurologic disease when performed in the early stages of cerebral adrenoleukodystrophy, but it is not effective for advanced cerebral ALD. HSCT does not reverse neurologic deficits present at transplantation, does not treat adrenal manifestations, and is not expected to prevent adult-onset adrenomyeloneuropathy.

    Atidarsagene autotemcel (Lenmeldy) is considered unproven for children with late juvenile MLD, adults with MLD, and patients treated within the last 6 months who have residual cells of donor origin.

    For Zevaskyn, targeted treatment areas previously treated with Zevaskyn are excluded from the initial medical-necessity criteria. A second treatment cycle for existing wounds or treatment of new wounds from previously untreated sites requires additional prior authorization.

    Casgevy and Lyfgenia are excluded when the patient has previously received gene therapy for the requested diagnosis.

    For Waskyra, coverage criteria exclude members with residual cells of donor origin from a prior HSCT, regardless of the time since transplantation.

    The documented sickle cell disease gene therapy criteria exclude members who have previously received gene therapy for the requested diagnosis.

    Clinical Thresholds and Coding Details

    Zynteglo transfusion dependence
    Annual volume thresholdAt least 100 mL/kg/year of packed red blood cell transfusions in each of the most recent two years
    Annual unit thresholdAt least 8 units/year of packed red blood cell transfusions in each of the most recent two years
    Applies toZynteglo transfusion-dependent beta-thalassemia criteria
    Zynteglo pre-treatment hemoglobin
    Hemoglobin targetHb ≥ 11 g/dL
    Before mobilizationMaintain the target for at least 30 days before mobilization
    Before conditioning

    Prior Authorization and Documentation

    Prior Authorization

    Zynteglo Prior Authorization Required

    Prior authorization is required before Zynteglo is administered as a one-time dose for transfusion-dependent β-thalassemia.

    • Applies to adult and pediatric patients who meet the policy criteria.
    • Submit clinical documentation supporting medical necessity and treatment eligibility.
    Prior Authorization

    Casgevy Prior Authorization Required

    Prior authorization is required before Casgevy is administered as a one-time dose for transfusion-dependent β-thalassemia.

    • Applies to patients aged 2 years and older who meet the policy criteria.
    • Submit clinical documentation supporting medical necessity and treatment eligibility.

    Therapy Overview

    Gene therapy introduces or modifies genetic material in target cells using a vector or other delivery system. Cellular therapy is a broader category that includes infusion of cellular products for hematopoietic reconstitution or for a direct immunologic effect. This guideline addresses autologous hematopoietic stem-cell gene therapies and a cell-sheet cutaneous gene therapy for FDA-approved inherited disorders.

    Key Definitions

    Gene therapy
    PurposeChanges gene expression to address disease-causing genetic abnormalities
    MechanismsReplaces or corrects a disease-causing gene, inactivates a target gene, or inserts a new or modified gene
    DeliveryUses a vector or other delivery system of genetic sequence, genetically modified microorganisms, viruses, or cells
    Cellular therapy
    CategoryA broad category of cellular products
    Hematopoietic useIncludes infusion of a cellular product for hematopoietic reconstitution
    Immunologic use

    Initial Therapy Criteria

    Zynteglo initial therapy criteria

    Zynteglo is considered medically necessary as a one-time single dose when all of the following are met.

    Required Zynteglo conditions: The patient has transfusion-dependent beta-thalassemia; meets the transfusion threshold; has a qualifying HBB genotype; is an allogeneic HSCT candidate but has no appropriate donor; meets the recommended pre-treatment hemoglobin target; has required infectious, hepatic, iron-overload, cardiac MRI, and oncology evaluations; has not previously received gene therapy for the requested diagnosis; and is at least 4 years old, weighs at least 6 kg, and is reasonably expected to provide sufficient cells for manufacturing.At least 100 mL/kg/year or 8 units/year of PRB transfusions; Hb ≥11 g/dL for at least 30 days before mobilization and conditioning; age ≥4 years; weight ≥6 kg

    Casgevy initial therapy criteria

    Casgevy is considered medically necessary as a one-time single dose when all of the following are met.

    Required Casgevy conditions: The patient is at least 2 years old with transfusion-dependent beta-thalassemia; meets the transfusion threshold; has a qualifying HBB genotype; is an allogeneic HSCT candidate but has no appropriate donor; has the recommended pre-apheresis hemoglobin goal; has negative HIV-1, HIV-2, HBV, and HCV screening; has not previously received gene therapy for the requested diagnosis; and has not previously received allogeneic or autologous HSCT.

    Continuation and Monitoring Criteria

    Lyfgenia post-treatment monitoring criteria

    Post-treatment monitoring is required after Lyfgenia.

    Lyfgenia long-term monitoring: Monitor for hematologic malignancy with complete blood counts every 6 months for at least 15 years after treatment and perform integration-site analysis at months 6 and 12 and as clinically warranted.CBC every 6 months for at least 15 years; integration-site analysis at months 6 and 12 and as warranted

    Lyfgenia carries a boxed warning for hematologic malignancy.

    Prerequisite Treatment Requirements

    StepRequirement
    Step 1Document compliance with hydroxyurea or another prescribed treatment regimen before Casgevy or Lyfgenia treatment.
    StepRequirement
    Step 2Document that the patient is a candidate for allogeneic HSCT but is ineligible because an appropriate donor is unavailable before Casgevy or Lyfgenia treatment.

    Treatment Quantity Limits

    Zynteglo and Casgevy quantity limit
    Zynteglo quantity limitOne-time single dose
    Casgevy beta-thalassemia quantity limitOne-time single dose
    Limit applies perCourse
    Skysona, Kresladi, or Lenmeldy quantity limits
    SkysonaOne-time single dose
    KresladiOne-time infusion
    LenmeldyOne-time infusion

    Site of Care Requirements

    Billing Rule

    Use the hospital outpatient site of care for Zevaskyn grafting

    Zevaskyn cultured sheets are surgically grafted onto RDEB wounds under general anesthesia in the hospital outpatient setting. Patients are hospitalized for at least one week postoperatively to optimize engraftment.

    Policy Summary
    PayerUnitedHealthcare
    PolicyGene Therapy Clinical Guideline
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOct 1, 2026
    Last ReviewSep 9, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization establishing all applicable diagnosis, genetic, clinical-severity, prior-treatment, donor-availability, and transplant-related medical necessity criteria before infusion.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Coding DetailsPrior Authorization and DocumentationTherapy OverviewKey DefinitionsInitial Therapy CriteriaContinuation and Monitoring CriteriaPrerequisite Treatment RequirementsTreatment Quantity LimitsSite of Care Requirements
    Maintain the target for at least 30 days before myeloablative conditioning
    Zynteglo age and weight
    Minimum age4 years
    Minimum weight6 kg
    Additional requirementThe patient is reasonably anticipated to provide at least the minimum number of cells required to initiate manufacturing
    Casgevy transfusion dependence
    Annual volume thresholdAt least 100 mL/kg/year of red blood cell transfusions in each of the most recent two years
    Annual unit thresholdAt least 10 units/year of red blood cell transfusions in each of the most recent two years
    Applies toCasgevy transfusion-dependent beta-thalassemia criteria
    Casgevy pre-apheresis hemoglobin
    Pre-apheresis goalHb ≥ 11 g/dL
    ManagementTransfuse before apheresis to maintain the hemoglobin goal
    TherapyCasgevy for transfusion-dependent beta-thalassemia
    Casgevy transfusion-independence endpoint
    Weighted average hemoglobinHb ≥ 9 g/dL
    Transfusion requirementNo red blood cell transfusions
    DurationAt least 12 consecutive months, evaluated beginning 60 days after the last post-transplant-support or disease-management transfusion
    Skysona eligible age
    Eligible age range4–17 years
    Sex requirementMale
    Disease settingEarly, active cerebral adrenoleukodystrophy
    Skysona neurologic function score
    Maximum scoreNeurologic function score ≤ 1
    Clinical statusAsymptomatic or mildly symptomatic
    Scale meaningLower scores indicate fewer neurologic symptoms
    Skysona Loes score
    Lower bound0.5
    Upper bound9
    AssessmentMRI-based Loes score measuring the location and extent of cerebral involvement and atrophy
    Severe LAD-I CD18 and infection criteria
    Pathway 1 CD18 expressionLess than 2% of normal CD18-expressing PMNs
    Pathway 1 infection historyAt least 1 grade 2 or higher bacterial or fungal infection
    Pathway 2At least 2% of normal CD18-expressing PMNs with fewer than 2% of PMNs expressing CD11a or CD11b
    ESEJ MLD motor function
    Motor-function thresholdGFMA-MLD 0–1
    PopulationEarly symptomatic early-juvenile metachromatic leukodystrophy
    UseRequired for the ESEJ MLD pathway
    ESEJ MLD IQ
    Minimum IQIQ ≥ 85
    PopulationEarly symptomatic early-juvenile metachromatic leukodystrophy
    UseRequired together with GFMA-MLD 0–1 for the ESEJ MLD pathway
    Zevaskyn treatment quantity
    Maximum quantityUp to 12 gene-corrected keratinocyte sheets
    AdministrationApplied during a single surgical session
    Additional cyclesA second treatment cycle requires additional prior authorization
    Casgevy severe VOC history
    Minimum frequency2 severe VOC events per year
    Look-back periodEach of the previous 2 years
    Total minimumAt least 4 severe VOC events across the two preceding years
    Casgevy transfusion plan
    HbS targetLess than 30% of total hemoglobin
    Total hemoglobin limitTotal hemoglobin concentration ≤ 11 g/dL
    TimingThe plan documents intent to transfuse before apheresis
    Lyfgenia VOE history
    Minimum VOE historyAt least 4 qualifying VOEs
    Look-back periodPrior 24 months
    PopulationPatients receiving Lyfgenia for sickle cell disease
    Lyfgenia transfusion plan
    Hemoglobin target8–10 g/dL
    Maximum hemoglobinNot to exceed 12 g/dL
    HbS targetHbS < 30%
    Lyfgenia post-treatment monitoring
    Complete blood countsEvery 6 months for at least 15 years after treatment
    Integration-site analysisAt months 6 and 12
    Additional analysisAs clinically warranted
    Qualifying vaso-occlusive events
    Minimum events4 qualifying vaso-occlusive events
    Time windowWithin the prior 24 months
    Event definitionIncludes acute pain lasting more than 2 hours, acute chest or hepatic or splenic sequestration, qualifying hospitalization or repeated urgent visits, or priapism requiring medical attention
    Transfusion target and HbS threshold
    Hemoglobin target8–10 g/dL
    Upper limitNot to exceed 12 g/dL
    HbS thresholdHbS < 30%
    Wiskott-Aldrich disease severity
    Clinical severityZhu clinical score ≥ 3
    Genetic severitySevere WAS mutation
    Protein expressionAbsent WASp expression
    Prior Authorization

    Skysona Prior Authorization and Request Contents

    Prior authorization is required before Skysona is administered as a one-time dose for early, active cerebral adrenoleukodystrophy (CALD). The request must include documentation establishing the diagnosis, disease severity, donor status, and required clinical clearances.

    • Patient must be a male aged 4–17 years with early, active CALD.
    • Include brain MRI findings, ABCD1 genetic testing, VLCFA levels, neurologic function score, Loes score, and hematology and hepatology clearances.
    • Include oncology clearance when there is a known prior or current malignancy.
    Prior Authorization

    Kresladi Prior Authorization and Documentation

    Prior authorization is required before Kresladi is administered as a one-time infusion for pediatric severe leukocyte adhesion deficiency-I (LAD-I).

    • Document biallelic ITGB2 variants confirmed by molecular genetic testing.
    • Document the applicable CD18/CD11a or CD11b findings and the absence of an available HLA-matched sibling donor.
    Prior Authorization

    Lenmeldy Prior Authorization Required

    Prior authorization is required before Lenmeldy is administered as a one-time infusion for qualifying metachromatic leukodystrophy (MLD).

    • Submit documentation of the qualifying pre-symptomatic late infantile, pre-symptomatic early juvenile, or early symptomatic early juvenile MLD diagnosis.
    • Document the applicable diagnostic confirmation and clinical criteria.

    Unsupported block type: prior_auth

    Prior Authorization

    Zevaskyn Initial Authorization and Surgical Application

    Prior authorization is required for Zevaskyn, which is administered as a surgical application of up to 12 gene-corrected keratinocyte sheets during a single surgical session for RDEB wounds.

    • Applies to pediatric and adult patients with recessive dystrophic epidermolysis bullosa wounds.
    • The request must establish the required genetic, skin, infection, malignancy, and treatment-site criteria.
    Prior Authorization

    Casgevy Initial Authorization for SCD

    Prior authorization is required before Casgevy is administered as a one-time infusion for sickle cell disease (SCD).

    • Applies to patients aged 2 years and older who meet the SCD criteria.
    • The request must document genotype, qualifying vaso-occlusive events, infectious-disease screening, transfusion planning, donor status, prior disease-directed treatment, and prior gene therapy or HSCT history.
    Prior Authorization

    Lyfgenia Initial Authorization for SCD

    Prior authorization is required before Lyfgenia is administered as a one-time infusion for SCD.

    • Applies to patients aged 12 years and older who meet the SCD criteria.
    • The request must document genotype, qualifying vaso-occlusive events, infectious-disease screening, transfusion planning, donor status, prior disease-directed treatment, and prior gene therapy history.
    Documentation Required

    Gene Therapy Prior Authorization Documentation

    Submit complete gene-therapy prior authorization documentation before treatment. Incomplete records may delay review or result in nonauthorization.

    • Include the diagnosis and qualifying genotype or molecular test results.
    • Include disease-severity and prior-treatment records, infectious-disease screening, transplant-donor assessment, transfusion or mobilization plan when applicable, and relevant contraindication or clearance evaluations.
    • Document that the patient has not previously received gene therapy for the requested diagnosis and include relevant HSCT history.
    Documentation Required

    Prior Disease-Directed Treatment Required

    Before Casgevy or Lyfgenia treatment for SCD, document compliance with hydroxyurea or another prescribed disease-directed treatment regimen.

    • Include the medication name, treatment history, adherence or compliance information, and clinical rationale when applicable.
    • This requirement applies to both Casgevy and Lyfgenia SCD requests.
    Documentation Required

    Allogeneic HSCT Donor Requirement

    Before Casgevy or Lyfgenia treatment for SCD, document that the patient is an appropriate candidate for allogeneic HSCT but is ineligible because an appropriate donor is unavailable.

    • Include the transplant evaluation and donor-search results.
    • The absence of an appropriate donor must be documented before mobilization, apheresis, or treatment as applicable.
    Documentation Required

    Zynteglo Clinical Documentation Checklist

    Provide the clinical documentation needed to demonstrate that Zynteglo criteria are met.

    • Transfusion dependence: at least 100 mL/kg/year or 8 units/year of packed red blood cell transfusions in each of the most recent two years.
    • HBB sequencing confirming a qualifying genotype, including non-β0/β0 or β0/β0 examples.
    • Allogeneic HSCT candidacy with ineligibility because no appropriate donor is available; document this before mobilization, apheresis, and myeloablative conditioning.
    • Document recommended Hb ≥11 g/dL for at least 30 days before mobilization and before myeloablative conditioning, when applicable.
    • Document HBV, HCV, HTLV-1/2, and HIV-1/2 screening; hepatology evaluation of abnormal liver function; iron-overload assessment with myocardial T2* MRI and a treatment plan if iron overload is present.
    • Document oncology evaluation and clearance for known prior or current malignancy, no prior gene therapy for the requested diagnosis, age ≥4 years, weight ≥6 kg, and anticipated ability to provide sufficient cells for manufacturing.
    Documentation Required

    Casgevy Clinical Documentation Checklist

    Provide documentation demonstrating that the patient meets Casgevy criteria for transfusion-dependent β-thalassemia.

    • Patient must be aged 2 years or older and transfusion-dependent, defined as at least 100 mL/kg/year or 10 units/year of RBC transfusions in each of the most recent two years.
    • Provide HBB sequencing confirming a qualifying β0/β0-like or non-β0/β0-like genotype.
    • Document allogeneic HSCT candidacy with ineligibility because no appropriate donor is available.
    • Document the recommended transfusion goal of Hb ≥11 g/dL before apheresis.
    • Provide confirmative screening showing no HIV-1, HIV-2, HBV, or HCV; document no prior gene therapy for the requested diagnosis and no prior allogeneic or autologous HSCT.
    Documentation Required

    Skysona Clinical Documentation Checklist

    Provide documentation demonstrating that the patient meets Skysona criteria and that required safety evaluations have been completed.

    • Document male sex, age 4–17 years, early active CALD, neurologic function score ≤1, Loes score 0.5–9, gadolinium enhancement on brain MRI, pathogenic or likely pathogenic ABCD1 variant, and elevated VLCFA levels.
    • Document that no HLA-matched donor is available for allogeneic HSCT.
    • Provide hematology clearance for adequate hematologic function and hepatology clearance for abnormal liver function.
    • Provide oncology clearance for known prior or current malignancy and document counseling or consultation with hematology experts regarding hematologic-malignancy risk and post-treatment monitoring.
    Documentation Required

    Kresladi Clinical Documentation Checklist

    Provide documentation demonstrating that the patient meets Kresladi criteria for severe pediatric LAD-I.

    • Provide molecular confirmation of biallelic ITGB2 variants.
    • Document either <2% normal CD18-expressing PMNs plus at least one grade 2 or higher bacterial or fungal infection, or ≥2% normal CD18-expressing PMNs when fewer than 2% of PMNs express CD11a or CD11b.
    • Document that no HLA-matched sibling donor is available for allogeneic HSCT.
    Documentation Required

    Lenmeldy Clinical Documentation Checklist

    Provide documentation demonstrating that the patient meets Lenmeldy criteria for qualifying MLD.

    • For pre-symptomatic late infantile or early juvenile MLD, document confirmation through testing of siblings of a previously affected child or positive newborn screening followed by formal diagnostic confirmation.
    • For early symptomatic early juvenile MLD, document GFMA-MLD 0–1 and IQ ≥85.
    • Document any applicable exception for impairments caused by non-MLD comorbidities or for a patient close to the IQ cutoff.
    Documentation Required

    Zevaskyn Clinical Documentation Checklist

    Provide documentation demonstrating that the patient meets Zevaskyn criteria for surgical application.

    • Document positive NC1 expression of type 7 collagen in the skin.
    • Document two confirmed RDEB C7 mutations with recessive inheritance or confirmation that the parents have no evidence of dominant disease.
    • Document no current systemic infection, including HIV, HBV, or HCV.
    • Document no current evidence or history of SCC in the targeted treatment areas and that the areas have not previously been treated with Zevaskyn.
    Documentation Required

    Casgevy SCD Clinical Documentation Checklist

    Provide documentation demonstrating that the patient meets Casgevy SCD criteria.

    • Patient must be aged 2 years or older with a molecularly confirmed βs/βs, βs/β0, or βs/β+ genotype.
    • Document at least two severe VOC events per year during each of the previous two years, including qualifying acute pain treatment, acute chest syndrome, priapism lasting more than two hours requiring facility care, or splenic sequestration.
    • Provide confirmative screening showing no HIV-1, HIV-2, HBV, or HCV.
    • Document the transfusion plan before apheresis: HbS <30% of total Hb while total Hb is maintained at ≤11 g/dL.
    • Document appropriate allogeneic HSCT candidacy with no appropriate donor, compliance with hydroxyurea or another prescribed regimen, no prior gene therapy for the requested diagnosis, and relevant HSCT history.
    Documentation Required

    Lyfgenia SCD Clinical Documentation Checklist

    Provide documentation demonstrating that the patient meets Lyfgenia SCD criteria.

    • Patient must be aged 12 years or older with a molecularly confirmed βs/βs, βs/β0, or βs/β+ genotype.
    • Document at least four qualifying VOEs during the prior 24 months.
    • Provide confirmative screening showing no HIV-1, HIV-2, HBV, or HCV.
    • Document the transfusion plan targeting Hb 8–10 g/dL, not exceeding 12 g/dL, and HbS <30%.
    • Document appropriate allogeneic HSCT candidacy with no appropriate donor, compliance with hydroxyurea or another prescribed regimen, and no prior gene therapy for the requested diagnosis.
    Documentation Required

    Lyfgenia Long-Term Monitoring Documentation

    For Lyfgenia, submit a long-term monitoring plan addressing the boxed warning for hematologic malignancy.

    • Plan complete blood counts every 6 months for at least 15 years after treatment.
    • Plan integration-site analysis at months 6 and 12 and thereafter as clinically warranted.
    • Document how abnormal results will be evaluated and managed.
    Documentation Required

    Required Sickle Cell Disease Records

    Submit the SCD records needed to verify disease severity and treatment eligibility for Casgevy or Lyfgenia.

    • Molecular or genetic test report confirming βs/βs, βs/β0, or βs/β+ genotype.
    • Records of qualifying VOCs or severe VOCs, including dates, facility visits, hospitalizations, medications, transfusions, and acute chest syndrome, sequestration, or priapism documentation when applicable.
    • Infectious-disease screening results for HIV-1, HIV-2, HBV, and HCV.
    • Hydroxyurea or other prescribed disease-directed treatment history and compliance documentation.
    • Transplant evaluation, donor-search results, transfusion plan, prior gene-therapy history, and relevant prior HSCT records.
    Documentation Required

    Required Waskyra Records

    Submit records confirming that the patient meets Waskyra eligibility requirements.

    • Document a confirmed WAS gene mutation and at least one of the following: Zhu clinical score ≥3, severe WAS mutation, or absent WASp expression.
    • Document that the patient is an appropriate HSCT candidate but has no suitable HLA-matched related stem-cell donor.
    • Document no HSCT within the 6 months before planned infusion, no residual donor-origin cells from any prior HSCT, and no prior gene therapy.
    Documentation Required

    Lyfgenia Long-Term Malignancy Monitoring Plan

    Include a long-term malignancy surveillance plan with Lyfgenia requests because hematologic malignancy has occurred after treatment.

    • Complete blood counts are required every 6 months for at least 15 years after treatment.
    • Integration-site analysis is required at months 6 and 12 and as warranted thereafter.
    • The plan should identify responsible clinicians, follow-up intervals, and escalation for abnormal findings.
    Denial Risk

    Zynteglo Eligibility Deficiencies and Denial Risks

    Zynteglo may be denied when the request does not establish all eligibility criteria or when required safety and manufacturing documentation is absent.

    • Insufficient transfusion dependence, missing qualifying HBB genotype, or failure to document allogeneic HSCT candidacy with no appropriate donor may result in denial.
    • Missing infectious screening, liver or iron-overload evaluation, oncology clearance when applicable, age or weight requirements, or adequate cell-collection potential may result in denial.
    • Prior gene therapy for the requested diagnosis is not eligible.
    Denial Risk

    Casgevy Eligibility Deficiencies and Denial Risks

    Casgevy may be denied when transfusion dependence, genotype, donor status, infection screening, or prior treatment history is not adequately documented.

    • The request must meet the applicable transfusion threshold and qualifying HBB genotype criteria.
    • Prior gene therapy or prior allogeneic or autologous HSCT for the requested diagnosis is not eligible.
    • Missing infectious-disease screening or failure to document an unavailable appropriate allogeneic HSCT donor may result in denial.
    Denial Risk

    Skysona Eligibility Criteria and Denial Risks

    Skysona may be denied when disease severity, diagnostic testing, donor status, or required safety clearances are not established.

    • The patient must be a male aged 4–17 years with early active CALD, neurologic function score ≤1, Loes score 0.5–9, gadolinium enhancement, a qualifying ABCD1 variant, and elevated VLCFA levels.
    • An available HLA-matched donor, inadequate hematologic function, or missing hematology, hepatology, or applicable oncology clearance may result in denial.
    • The serious hematologic-malignancy risk requires appropriate expert consultation and monitoring planning.
    Denial Risk

    Kresladi Eligibility Criteria and Denial Risks

    Kresladi may be denied when molecular, hematologic, infectious-complication, or donor criteria are not met.

    • Biallelic ITGB2 variants must be confirmed through molecular genetic testing.
    • The applicable CD18 and CD11a/CD11b criteria and qualifying infection history must be documented.
    • An available HLA-matched sibling donor does not meet the policy requirement.
    Denial Risk

    Lenmeldy Unsupported Populations

    Lenmeldy is not supported for populations outside the policy's qualifying MLD indications.

    • The policy does not support children with late juvenile MLD.
    • The policy does not support patients with adult MLD.
    • The policy does not support children or adults treated within the last six months who have residual cells of donor origin.
    Denial Risk

    Lenmeldy Unproven Populations

    Lenmeldy is considered unproven when evidence is insufficient for the requested population or circumstances.

    • Requests for late juvenile MLD or adult MLD are unproven.
    • Requests for treatment within six months when residual cells of donor origin remain are unproven.
    • Requests that do not document a qualifying pre-symptomatic or early symptomatic early juvenile MLD diagnosis may be denied.
    Denial Risk

    Zevaskyn Eligibility Requirements and Denial Risks

    Zevaskyn may be denied when the RDEB diagnosis, skin findings, infection status, malignancy status, or treatment-site requirements are not met.

    • Document positive NC1 expression, the required RDEB C7 mutation pattern, and absence of systemic infection.
    • Targeted areas must have no current evidence or history of SCC and must not have been previously treated with Zevaskyn.
    • A second cycle or treatment of new wounds at previously untreated sites requires additional prior authorization.
    Denial Risk

    Casgevy SCD Authorization Failures

    Casgevy SCD authorization may fail when genotype, age, VOC history, screening, transfusion planning, donor status, or prior-treatment requirements are not met.

    • Patient must be aged 2 years or older with a qualifying genotype and at least two severe VOC events per year during each of the prior two years.
    • Missing confirmation of no HIV-1, HIV-2, HBV, or HCV, or missing the required pre-apheresis transfusion plan may result in denial.
    • Failure to document compliance with hydroxyurea or another prescribed regimen, an unavailable appropriate donor, or no prior gene therapy may result in denial.
    Denial Risk

    Lyfgenia Authorization Failures

    Lyfgenia authorization may fail when the required SCD criteria and supporting records are incomplete or not met.

    • Patient must be aged 12 years or older with a qualifying genotype and at least four qualifying VOEs during the prior 24 months.
    • Missing infectious-disease screening, transfusion targets, donor documentation, or prior disease-directed treatment compliance may result in denial.
    • Prior gene therapy for the requested diagnosis is not eligible; the request must also include the required malignancy-monitoring plan.
    Denial Risk

    Sickle Cell Disease Criteria Not Met

    SCD criteria are not met when the genotype, event history, age, donor, treatment, or safety requirements for Casgevy or Lyfgenia are absent.

    • Casgevy requires age ≥2 years and at least two severe VOC events per year during each of the previous two years.
    • Lyfgenia requires age ≥12 years and at least four qualifying VOEs during the prior 24 months.
    • For either therapy, document a qualifying genotype, negative HIV/HBV/HCV screening, an unavailable appropriate allogeneic HSCT donor, compliance with hydroxyurea or another prescribed regimen, and no prior gene therapy for the requested diagnosis.
    • The applicable transfusion plan must be documented: Casgevy requires HbS <30% with total Hb ≤11 g/dL; Lyfgenia requires Hb 8–10 g/dL, no more than 12 g/dL, and HbS <30%.
    Denial Risk

    Waskyra Eligibility Criteria Not Met

    Waskyra may be denied when the WAS diagnosis, severity, donor status, prior HSCT, residual donor-cell, or prior gene-therapy requirements are not met.

    • Document a confirmed WAS mutation plus Zhu clinical score ≥3, a severe WAS mutation, or absent WASp expression.
    • The patient must have no suitable HLA-matched related donor and must not have received HSCT within the preceding 6 months.
    • There must be no residual cells of donor origin from any prior HSCT and no prior gene therapy.
    Includes infusion of a cellular product intended to have a direct immunologic impact
    Transfusion-dependent beta-thalassemia
    ConditionBeta-thalassemia requiring regular red blood cell transfusions
    Zynteglo thresholdAt least 100 mL/kg/year or 8 units/year of packed red blood cell transfusions in the most recent two years
    Casgevy thresholdAt least 100 mL/kg/year or 10 units/year of red blood cell transfusions in the most recent two years
    Transfusion independence
    Hemoglobin criterionWeighted average hemoglobin ≥ 9 g/dL
    Transfusion criterionNo red blood cell transfusions
    DurationAt least 12 consecutive months, beginning 60 days after the last post-transplant-support or disease-management transfusion
    Loes score
    Assessment typeMRI-based severity scale
    Range0–34 points
    MeasuresLocation and extent of cerebral involvement and atrophy in cerebral adrenoleukodystrophy
    Neurologic function score
    Assessment typeALD-specific neurologic function scale
    DomainsAssesses 15 neurologic disabilities
    InterpretationLower scores indicate fewer symptoms; higher scores indicate greater disability
    Major functional disability
    CommunicationLoss of communication or cortical blindness
    Support needsTube feeding, total incontinence, or wheelchair dependence
    Motor functionComplete loss of voluntary movement
    Severe LAD-I
    CD18 expressionLess than 2% of CD18-expressing neutrophils
    Clinical courseRecurrent, life-threatening bacterial and other infections
    DiseaseSevere leukocyte adhesion deficiency type I
    GMFC-MLD
    PurposeMotor-function classification system used in metachromatic leukodystrophy
    Severe impairmentGMFC-MLD level 5 or higher
    Clinical endpointIncludes loss of locomotion and loss of sitting without support at level ≥ 5
    Severe VOC
    Acute pain eventRequires a medical-facility visit and opioid or intravenous NSAID treatment or red blood cell transfusion
    Other qualifying eventsAcute chest syndrome or splenic sequestration
    PriapismLasts more than 2 hours and requires a medical-facility visit
    VOE
    Pain eventAcute pain without another medically determined cause lasting more than 2 hours
    Acute complicationsAcute chest syndrome or acute hepatic or splenic sequestration
    Other eventsQualifying hospitalization or repeated emergency or urgent-care visits with IV medication, or priapism requiring medical attention
    Globin response
    HbA T87Q proportionWeighted average hemoglobin A T87Q percentage of nontransfused total hemoglobin ≥ 30%
    Hemoglobin alternativeWeighted average nontransfused total hemoglobin increases by ≥ 3 g/dL from baseline or reaches ≥ 10 g/dL
    DurationCriteria maintained for at least 6 months after infusion
    NC1-positive status
    MarkerNoncollagenous region 1 of type VII collagen
    StatusConfirmed positive expression
    Tissue testedSkin
    Vaso-occlusive event
    Pain eventAcute pain without another medically determined cause lasting more than two hours
    Sickle complicationsAcute chest syndrome or acute hepatic or splenic sequestration
    Additional qualifying eventsHospitalization or multiple emergency or urgent-care visits over 72 hours with IV medications, or priapism requiring any medical attention
    Wiskott-Aldrich syndrome
    Disease typeRare X-linked primary immunodeficiency
    Genetic causePathogenic variants in the WAS gene
    Protein encodedWiskott-Aldrich syndrome protein (WASp)
    At least 100 mL/kg/year or 10 units/year of RBC transfusions; age ≥2 years; pre-apheresis Hb goal ≥11 g/dL

    Skysona initial therapy criteria

    Skysona is a one-time single dose for eligible patients with early, active cerebral ALD.

    Skysona eligibility: The patient is a male aged 4–17 years with early, active cerebral adrenoleukodystrophy; has no available HLA-matched donor; has neurologic function score ≤1, a Loes score of 0.5–9, gadolinium enhancement on brain MRI, a pathogenic or likely pathogenic ABCD1 variant, and elevated VLCFA levels; and has required hematologic, hepatic, and oncology evaluations and clearances.Male age 4–17 years; NFS ≤1; Loes score 0.5–9

    Hematology consultation is highly recommended before treatment because of hematologic malignancy risk.

    Kresladi initial therapy criteria

    Kresladi is a one-time intravenous infusion for pediatric severe LAD-I.

    Kresladi eligibility

    • Qualifying PMN/CD18 pathway

      • Less than 2% of normal CD18-expressing PMNs and at least one grade 2 or higher bacterial or fungal infection.<2% CD18-expressing PMNs; ≥1 qualifying infection
      • At least 2% of normal CD18-expressing PMNs and fewer than 2% of PMNs express CD11a or CD11b.≥2% CD18-expressing PMNs; <2% CD11a or CD11b

    Lenmeldy initial therapy criteria

    Lenmeldy is a one-time intravenous infusion for eligible pediatric MLD.

    Eligible MLD presentation

    • Confirmed presymptomatic late-infantile or early-juvenile MLD through testing of siblings of a previously affected and diagnosed child, or through positive newborn screening followed by formal diagnostic confirmation testing.PSLI or PSEJ
    • Early symptomatic early-juvenile MLD with GFMA-MLD 0–1 and IQ ≥85.GFMA-MLD 0–1; IQ ≥85

    Zevaskyn initial therapy criteria

    Zevaskyn is medically necessary for pediatric and adult patients with RDEB wounds when all listed criteria are satisfied.

    Zevaskyn eligibility: The patient has NC1-positive skin expression; two recessive RDEB C7 mutations or parental evidence excluding dominant disease; no current HIV, HBV, or HCV infection; no current or historical SCC in targeted areas; and no prior Zevaskyn treatment of targeted areas.Up to 12 gene-corrected keratinocyte sheets during one surgical session

    Additional prior authorization is required for a second cycle or new wounds from previously untreated sites.

    Casgevy SCD initial therapy criteria

    Casgevy is medically necessary as a one-time infusion when all listed criteria are satisfied.

    Casgevy SCD eligibility: The patient is at least 2 years old; has a molecularly or genetically confirmed βs/βs, βs/β0, or βs/β+ genotype; has at least two severe VOCs per year during each of the preceding two years; has negative HIV-1, HIV-2, HBV, and HCV screening; has the specified pre-apheresis transfusion plan; is an allogeneic HSCT candidate without an appropriate donor; complies with hydroxyurea or another prescribed regimen; and has no prior gene therapy for the diagnosis.At least 2 severe VOCs per year for 2 years; HbS <30%; total Hb ≤11 g/dL

    Lyfgenia initial therapy criteria

    Lyfgenia is medically necessary as a one-time infusion when all listed criteria are satisfied.

    Lyfgenia SCD eligibility: The patient is at least 12 years old; has a molecularly or genetically confirmed βs/βs, βs/β0, or βs/β+ genotype; has at least four qualifying VOEs during the preceding 24 months; has negative HIV-1, HIV-2, HBV, and HCV screening; has the specified transfusion plan; is an allogeneic HSCT candidate without an appropriate donor; complies with hydroxyurea or another prescribed regimen; and has no prior gene therapy for the diagnosis.At least 4 VOEs in 24 months; hemoglobin 8–10 g/dL and not above 12 g/dL; HbS <30%

    One-time infusion with boxed warning for hematologic malignancy.

    Waskyra initial therapy criteria

    Waskyra is medically necessary as a one-time infusion in pediatric patients aged 6 months and older and adults with Wiskott-Aldrich syndrome when all criteria are met.

    Waskyra initial therapy: The member has a confirmed WAS mutation and at least one qualifying severity feature; is an appropriate HSCT candidate without a suitable HLA-matched related donor; has not received HSCT within 6 months before planned infusion; has no residual donor-origin cells from a prior HSCT; and has not received prior gene therapy.Age ≥6 months; Zhu score ≥3, severe WAS mutation, or absent WASp expression; no HSCT within prior 6 months

    Sickle cell disease gene therapy criteria

    The documented sickle cell disease gene therapy criteria require all listed conditions.

    Sickle cell disease gene therapy: The member must have a molecularly or genetically confirmed βs/βs, βs/β0, or βs/β+ genotype; at least four qualifying VOEs in the prior 24 months; negative HIV-1, HIV-2, HBV, and HCV screening; a transfusion plan targeting hemoglobin 8–10 g/dL without exceeding 12 g/dL and HbS below 30%; HSCT candidacy without an appropriate donor; documented compliance with hydroxyurea or another prescribed regimen; and no prior gene therapy for the requested diagnosis.≥4 VOEs in 24 months; Hb 8–10 g/dL; HbS <30%
    Zevaskyn quantity limit
    Maximum quantityUp to 12 gene-corrected keratinocyte sheets
    AdministrationDuring a single surgical session
    ProductPrademagene zamikeracel (Zevaskyn)
    Casgevy quantity limit
    Quantity limitOne infusion
    ProductExagamglogene autotemcel (Casgevy)
    BasisPer course
    Lyfgenia quantity limit
    Quantity limitOne infusion
    ProductLovotibeglogene autotemcel (Lyfgenia)
    BasisPer course
    Waskyra quantity limit
    Quantity limitOne-time infusion
    ProductWaskyra
    BasisPer course